Methods| All kidney transplant recipients followed up in the outpatient Kidney Transplantation
Department of Strasbourg University Hospital between January 20, 2021, and June 3, …

2 (SARS-CoV-2) have not been specifically investigated in kidney transplant recipient (KTRs).
Preliminary results suggest that among KTRs who received the first injection of an mRNA-…

To the editor: Several of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines use a nucleosidemodified, purified mRNA lipid nanoparticle-encapsulated …

Objectives To provide an overview of the spectrum, characteristics and outcomes of neurologic
manifestations associated with severe acute respiratory syndrome coronavirus 2 (SARS-…

Background and purpose Neurological manifestations in coronavirus disease (COVID)‐2019
may adversely affect clinical outcomes. Severe COVID‐19 and uremia are risk factors for …

Background Overimmunosuppression is a widely recognized risk factor for BK virus (BKV)
infection, particularly with the combination of tacrolimus, mycophenolate mofetil (MMF), and …

The cilgavimab−tixagevimab combination retains a partial in vitro neutralizing activity against
the current SARS‐CoV‐2 variants of concern (omicron BA.1, BA.1.1, and BA.2). Here, we …

Inadequately treated thyroid storm can lead to death. Therapeutic plasma exchange (TPE)
is a suggested treatment when conventional treatments fail, but its indication is not well …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has spread widely, causing
coronavirus disease 2019 (COVID‐19) and significant mortality. However, data on viral …

To the editor: After the publication of the 2 letters by Negrea and Rovin 1 and Rahim et al., 2
we herein describe 3 additional patients with IgA nephropathy (IgAN) who developed gross …